• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Inogen affirms 2014 outlook, predicts 2015 growth of up to 25%

Inogen affirms 2014 outlook, predicts 2015 growth of up to 25%

December 16, 2014 By Val Kennedy

Inogen affirms 2014 view, predicts 2015 revenue growth of up to 25%

Inogen (NSDQ:INGN) today affirmed its guidance for the rest of this year and issued its 2015 financial forecast, saying it expects to post top-line growth of 20% to 25% over 2014.

The respiratory products maker said it still expects adjusted net income of between $5.5 million and $6 million on sales of $106 million to $110 million this year.

For 2015, Inogen forecast for adjusted net income of $8 million to $9.5 million, on sales growth of 20% to 25%, or between $130 million and $135 million – fueled in part by a more than 30% expected rise in direct-to-consumer sales.

“The company expects positive cash flow for the year with no additional equity capital required to meet its current plan,” Inogen said in a press release.

Inogen reported that 2013 revenue soared 55% year-over-year, to $75.4 million. Net income rose to $18.2 million, or $1.10 per share, from a loss of $5.2 million, or $19.97 per share, for the previous year. Excluding a 1-time tax benefit, Inogen would have posted 2013 earnings of $3.6 million, the Goleta, Calif.-based company said.

“Oxygen therapy is a large and growing market opportunity estimated to include 2.5 to 3 million patients in the U.S. and representing an approximately $3 to $4 billion market. Portable oxygen concentrators continue to be the fastest-growing oxygen equipment segment in the United States,” CEO Raymond Huggenberger said in prepared remarks. “In 2013, Inogen was the leading POC supplier in the U.S. for Medicare patients. That momentum has continued into 2014 as we saw better-than-expected results from our direct-to-consumer sales strategy shift, as well as an increase in domestic business-to-business sales, primarily due to consumer awareness and demand. As we look towards 2015, we see multiple avenues to drive our future growth, including the expansion of our direct-to-consumer network and an increase in our business-to-business distribution, both domestic and international.”

Inogen issued its 2015 financial forecast during a meeting with investors and analysts in New York today. The company held an initial public offering in February, raising $52.5 million after underwriting fees.

INGN shares closed up 0.3% at $24.94 apiece today. The stock is up 55.9% since its March debut at $16 per share.

Filed Under: News Well, Respiratory, Wall Street Beat Tagged With: Inogen

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy